this is dr katherine o'brien speaking. out the im ortant katherine o'brien speaking.ne, it has demonstrated efficacy and safety, and it is an important vaccine for the world. given the short supply that we have in vaccines. and in taking all of the evidence under advisement, this very recent evidence about this small trial that is inconclusive around its findings, albeit demonstrating a low efficacy against mild and moderate disease, with no evidence to point in one direction or another on severe disease, so we have an absence of evidence from that trial about whether or not the product has efficacy against severe disease, hospitalisation and death, and that is the outcome of most interest and most impact for early roll—out of vaccines. we do have, site having reviewed all of this evidence, which was presented to them on monday afternoon, along with the evidence on variants of other types, the bay 117 variant as well, and we do have an assessment from sage that there is a plausible expectation that the vaccine will have impact, efficacy against severe disease, albeit